High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Fenneke Zwierenga*, Bianca van Veggel, Lizza E.L. Hendriks, T. Jeroen N. Hiltermann, Birgitta I. Hiddinga, Lucie B.M. Hijmering Kappelle, Arja ter Elst, Sayed M.S. Hashemi, Anne Marie C. Dingemans, Cor van der Leest, Adrianus J. de Langen, Michel M. van den Heuvel, Anthonie J. van der Wekken
Research output: Contribution to journal › Article › Academic › peer-review
6Citations
(Scopus)
47Downloads
(Pure)
Fingerprint
Dive into the research topics of 'High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial'. Together they form a unique fingerprint.